Naohiko Kodo; Shoei Sakata; Toshiro Matsuda
Nucleus (India) Springer India 58 (3) 231 - 234 0976-7975 2015/12
[Refereed] Gain-of-function mutations of Saccharomyces cerevisiae pleiotropic drug resistance (PDR) genes PDR1, PDR3, and YRR1 cause constitutive high expression of membrane-associated drug efflux pumps, resulting in the excretion of antifungal drugs. We previously identified a novel mutation of YRR1 that conferred salicylic acid (SA) resistance to S. cerevisiae BY4741 cells randomly mutagenized with ethyl methane sulfonate. Yeast cells carrying the yrr1–52 allele activated several drug efflux pumps and exhibited resistance to 4-nitroquinoline-N-oxide and cycloheximide. However, the activated genes and other factors that are directly involved in SA resistance remain unclear. Therefore, microarray analyses of total RNA extracted from yrr1–52 and wild-type cells during the logarithmic phase were performed. Twenty genes demonstrating >
2-fold higher expression than the wild-type were selected. Among the upregulated genes, YOR1, SNQ2, AZR1, and FLR1 encode transport proteins previously associated with drug efflux pumps. YOR1 and SNQ2, which encode an ATP-binding cassette (ABC) transporter, were investigated as candidate genes involved in SA resistance. Spot assay results showed no changes in SA susceptibility after disruption of YOR1 or SNQ2 on a background of YRR1 and yrr1–52, indicating that Yor1p and Snq2p are not involved in SA resistance.